Crossmark

Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018

Crossref DOI link: https://doi.org/10.1186/s12936-021-03930-9

Published Online: 2021-10-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chidimatembue, Arlindo

Svigel, Samaly S.

Mayor, Alfredo

Aíde, Pedro

Nhama, Abel

Nhamussua, Lídia

Nhacolo, Arsénio

Bassat, Quique

Salvador, Crizólgo

Enosse, Sónia

Saifodine, Abuchahama

De Carvalho, Eva

Candrinho, Baltazar

Zulliger, Rose

Goldman, Ira

Udhayakumar, Venkatachalam

Lucchi, Naomi W.

Halsey, Eric S.

Macete, Eusébio
Funding

Funding for this research was provided by:

united states agency for international development (RFA-656-16-00004)
License Information

Text and Data Mining valid from 2021-10-12

Version of Record valid from 2021-10-12
More Information

Article History

Received: 18 June 2021

Accepted: 26 September 2021

First Online: 12 October 2021

Declarations

:

: The study was reviewed and approved by the National Bioethics Committee for Health of Mozambique (CNBS—IRB00002657) on December 13, 2017, (Ref. 516/CNBS/17). The Office of the Associate Director for Science in the Center for Global Health at Centers for Disease Control and Prevention (CDC) determined the work to be a non-engaged research activity without requirement for CDC IRB review (Ref. 2017-361).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below